General (145) Partnerships (34) New Products (8) Acquisitions (6) New Technologies (3) Financials (2)
Pharma and Biotech (161) Corporate (14) Bioscience (8)
2020 (34) 2019 (32) 2018 (25) 2017 (23) 2016 (28) 2015 (12) 2014 (7)
Showing 1‐20 of 161
results per page
19 Nov 2020
Lonza and Be The Match BioTherapies partner to expand Vein-to-Vein Cell and Gene Therapy Supply Chain Network
Be The Match BioTherapies as a preferred partner to provide consistent access to high-quality, healthy donor tissue and cell and gene therapy (CGT)...
18 Nov 2020
Lonza Expands Highly Potent Drug Product Development and Manufacturing Capabilities
Highly potent capability implemented in Lonza-Tampa (US) product development labsHighly potent capable Gerteis roller compactor installed for...
16 Nov 2020
Lonza Congratulates Moderna on Interim Phase 3 Clinical Trial Data
Basel, Switzerland, 16 November 2020Quote from Pierre-Alain Ruffieux, Chief Executive Officer, Lonza:“We congratulate Moderna on this important...
12 Nov 2020
FUJIFILM Cellular Dynamics and Lonza Agree to Expand the Availability and Use of Induced Pluripotent Stem Cell Technology
FUJIFILM Cellular Dynamics grants Lonza a non-exclusive right to use their patents related to iPSC generation, including episomal vectors and...
10 Nov 2020
Altimmune Adds Lonza as a Manufacturing Partner for Supply of AdCOVID, its Single-Dose Intranasal Vaccine Candidate for COVID-19
AdCOVID, a single-dose intranasal vaccine for COVID-19, designed to generate a broad immune response with the unique ability to promote nasal...
09 Nov 2020
Lonza and Ypsomed enter into a Collaboration for Development and Manufacturing of Patch Injector-based Combination Products for Pharmaceutical customers
The collaboration will streamline the development of patch-injector-based combination products, especially for biologicsThe resulting products aim...
05 Nov 2020
Lonza Celebrates the Grand Opening of a New Facility for ADC Payload Manufacturing
The first manufacturing suite at the Visp (CH) site is dedicated to the manufacturing of antibody-drug conjugate drug-linker and complementary to...
30 Oct 2020
Lonza Announces Agreement to Manufacture AstraZeneca's COVID-19 Long-Acting Antibody Combination
The agreement will provide capacity for the manufacturing of AZD7442, currently being developed for the potential prevention and treatment of...
22 Oct 2020
Lonza Expands Its Capsule Manufacturing Capacity
Investment of CHF85m will expand capsule manufacturing capacity by 30 billion capsules annuallyThe new expansion involves eight global Lonza...
21 Sep 2020
Lonza Announces Scientific Advisory Board to Further Strengthen Drug Discovery Solutions & Services
Lonza has announced the formation of a new Scientific Advisory Board to advance in vitro ADME-Tox programs within its Bioscience Business UnitThe...
17 Sep 2020
LamKap Bio Group and Lonza Collaborate to Manufacture Bispecific Antibodies for Cancer Treatment
LamKap Bio Group develops fully human bispecific κλ antibodies targeting malignant cells in solid cancersLonza to provide cell line development,...
15 Sep 2020
Humanigen and Lonza Announce Collaboration to Expand Manufacturing of Humanigen's COVID-19 Therapeutic Candidate Lenzilumab
Collaboration to expand lenzilumab manufacturing capacity in advance of potential Emergency Use Authorization in 2020Commercial manufacturing to...
08 Sep 2020
Sheba Medical Center Treats First Patient with CAR-T Cell Immunotherapy Manufactured Using the Lonza Cocoon® Platform
First cancer patient dosed at Sheba Medical Center, Isreal with autologous CAR-T therapy manufactured using Lonza’s Cocoon® PlatformIsraeli...
27 Aug 2020
Lonza Prices CHF 150 Million Straight-Bond with a 0.350% Coupon
20 Aug 2020
IsoPlexis and Lonza Collaborate to Enable the Next Generation of Precision Cell Therapy Manufacturing
Lonza to utilize of IsoPlexis' IsoLight® automated proteomics platformIsoLight® to be used for functional quality analytics for cell therapy...
04 Aug 2020
Lonza Expands Microbial Capacity and Extends Long-term Partnership with Servier for L-asparaginase API Manufacturing
New mid-scale microbial facility to support Servier with active pharmaceutical ingredient (API) for acute lymphoblastic leukemia (ALL)...
27 Jul 2020
Lonza's Ibex Dedicate to Support the Commercial Manufacture of Kodiak’s KSI-301 - an Antibody Biopolymer Conjugate for Retinal Diseases
•  Purpose-built bioconjugation facility in Lonza’s Ibex™ Dedicate Biopark to support the potential commercial launch of Kodiak's leading...
13 Jul 2020
Junshi Biosciences and Lonza Partner to Produce a Neutralizing Antibody Tackling COVID-19
Junshi Biosciences developing therapies for COVID-19 in collaboration with a number of global partnersJunshi Biosciences' first SARS-CoV-2...
08 Jul 2020
Lonza Establishes Center of Excellence for Integrated Dry Powder Inhaler Product Development Services
Lonza establishes a new Center of Excellence to leverage its core particle engineering expertise utilizing both particle size reduction and spray...
01 Jul 2020
Lonza Expands Particle Engineering Services
Lonza doubles the network jet-milling capacity for supporting development stage projects and expands the capabilities in specialized cGMP...
1 2 3 4 ... 9 >